NIPH Clinical Trials Search

An examination of preventive effect of Carperitide for contrast induced nephropathy (CIN) in chronic kidney disease (CKD) patients

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	CKD with coronary artery disease
Date of first enrollment	2010/05/01
Target sample size	100
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Carperitide group (intra-venous continuous injection of 0.025-0.05ug/kg/min 18-24h before and 6h after PCI or coronary angiography) Control group (intra-venous continuous injection of 5% glucose 18-24h before and 6h after PCI or coronary angiography)

Outcome(s)

Primary Outcome

1.acute and sub-acute renal injury after intervention or coronary angiography (chages of L-FABP, N-gal, Midkine, eGFR, urinary albumin, urinary creatinine and serum creatunine within 24h after contrast use) 2.renal injury at 48h and 7days after intervention or coronary angiography (changes of eGFR, urinary albumin, urinary creatinine, serum creatinine, L-FABP, N-gal, Midkine and cystatin C at 48h and 7days after contrast use)

Secondary Outcome

incidence of adverse effects of Carperitide

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1.Patients with hemodialysis 2.cases with used contrast volume under 40ml, or over 300ml 3.Patients with previous adverse effect with Carperitide 4.female with pregnancy or possibility of pregnancy 5.Patients who judged that the medical attendant was inappropriate